Titre original:
SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity; a randomised, double-blind, parallel group, placebo-controlled trial comparing semaglutide 2.4 mg with semaglutide placebo both administered s.c. once-weekly in subjects with established CV disease and overweight or obesity
Indication (pathologie):
Cardiovascular disease
Identifiant SNOMED-CT:
49601007
Indication (pathologie):
Obesity
Identifiant SNOMED-CT:
414916001
Phase de l'étude:
Phase III
Recrutement:
Ouvert
Service:
Investigateur principal:
Van de Borne Philippe
Sponsor:
Novo Nordisk Pharma
Tél contact:
02 555 3907
Email contact:
Adresse hôpital:
Cliniques Universitaires de Bruxelles Hôpital Erasme
Route de Lennik 808,1070 Bruxelles, Belgique